The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins
Open accessAbstract
Background Plasma apolipoprotein B (apoB) is a composite measure of all apoB-containing lipoproteins causing atherosclerotic cardiovascular disease; however, it is unclear which fraction of risk is explained by cholesterol and triglycerides, respectively, in very low-density lipoproteins (VLDLs). Objectives The authors tested the hypothesis that VLDL cholesterol and triglycerides each explain part of the myocardial infarction risk from apoB-containing lipoproteins. Methods Nested within 109,751 individuals from the Copenhagen General Population Study, the authors examined 25,480 subjects free of lipid-lowering therapy and myocardial infarction at study entry. All had measurements of plasma apoB (quantitating number of apoB-containing lipoproteins) and cholesterol and triglyceride content of VLDL, intermediate-density lipoproteins (IDLs), and low-density lipoproteins (LDLs). Results During a median 11 years of follow-up, 1,816 were diagnosed with myocardial infarction. Per 1-mmol/l higher levels, multivariable-adjusted hazard ratios for myocardial infarction were 2.07 (95% confidence interval [CI]: 1.81 to 2.36) for VLDL cholesterol, 1.19 (95% CI: 1.14 to 1.25) for VLDL triglycerides, 5.38 (95% CI: 3.73 to 7.75) for IDL cholesterol, and 1.86 (95% CI: 1.62 to 2.14) for LDL cholesterol. Per 1-g/l higher plasma apoB, the corresponding value was 2.21 (95% CI: 1.90 to 2.58). In a step-up Cox regression, risk factors for myocardial infarction entered by importance as VLDL cholesterol, systolic blood pressure, smoking, and IDL + LDL cholesterol, whereas VLDL triglycerides did not enter the model. VLDL cholesterol explained 50% and IDL + LDL cholesterol 29% of the risk of myocardial infarction from apoB-containing lipoproteins, whereas VLDL triglycerides did not explain risk. Conclusions VLDL cholesterol explained one-half of the myocardial infarction risk from elevated apoB-containing lipoproteins, whereas VLDL triglycerides did not explain risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have suggested that TG and remnant cholesterol may be more potent risk factors for myocardial infarction (MI) than LDL-C is.2,3”
From Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
The Danish Civil Registration System
Pedersen, C. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810387965 · Cited by 4,713
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Cited by
Sorted by citations
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationMetabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Marston, N. A., Giugliano, R. P., Melloni, G. E. M., Park, J.-G., Morrill, V., Blazing, M. A., Ference, B., Stein, E., Stroes, E. S., Braunwald, E., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.5083 · Cited by 262
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 247
Wadström, B. N., Wulff, A. B., Pedersen, K. M., Jensen, G. B., & Nordestgaard, B. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab705 · Cited by 234
Self-citationHegemony of inflammation in atherosclerosis and coronary artery disease
Attiq, A., Afzal, S., Ahmad, W., & Kandeel, M. K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176338 · Cited by 251
Self-citationTardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac822 · Cited by 216
Self-citationExosomes in atherosclerosis: performers, bystanders, biomarkers, and therapeutic targets
Wang, C., Li, Z., Liu, Y., & Yuan, L. (2021) · Theranostics · doi:10.7150/thno.56035 · Cited by 194
Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk
Burnett, J. R., Hooper, A. J., & Hegele, R. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.029 · Cited by 122
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL)
Huang, J.-K., & Lee, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084300 · Cited by 115
Obesity Affects HDL Metabolism, Composition and Subclass Distribution
Stadler, J. T., Lackner, S., Mörkl, S., Trakaki, A., Scharnagl, H., Borenich, A., Wonisch, W., Mangge, H., Zelzer, S., Meier‐Allard, N., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030242 · Cited by 85
Triglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 87
Kelly, R. K., Tong, T. Y. N., Watling, C. Z., Reynolds, A. N., Piernas, C., Schmidt, J. A., Papier, K., Carter, J. L., Key, T. J., & Perez‐Cornago, A. (2023) · BMC Medicine · doi:10.1186/s12916-022-02712-7 · Cited by 87
High Remnant Cholesterol Level Potentiates the Development of Hypertension
Chen, M.-M., Huang, X., Xu, C., Song, X.-H., Liu, Y.-M., Yao, D., Lu, H., Wang, G., Zhang, G.-L., Chen, Z., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.830347 · Cited by 78
Excess Apolipoprotein B and Cardiovascular Risk in Women and Men
Johannesen, C. D. L., Langsted, A., Nordestgaard, B. G., & Mortensen, M. B. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.423 · Cited by 81
Self-citationLevin, M. G., Zuber, V., Walker, V. M., Klarin, D. M., Lynch, J. A., Malik, R., Aday, A. W., Bottolo, L., Pradhan, A. D., Dichgans, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053797 · Cited by 63
New Therapies for Lowering Triglyceride-Rich Lipoproteins
Rosenson, R. S., Shaik, A., & Song, W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.051 · Cited by 68
Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
Heo, J. H., & Jo, S.-H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e295 · Cited by 58
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
Luo, F., Das, A., Khetarpal, S. A., Fang, Z., Zelniker, T. A., Rosenson, R. S., & Qamar, A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.008 · Cited by 58
Ala‐Korpela, M., Zhao, S., Järvelin, M., Mäkinen, V., & Ohukainen, P. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab156 · Cited by 57
Stellaard, F. (2022) · Nutrients · doi:10.3390/nu14081643 · Cited by 59
Packard, C. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00994-z · Cited by 54
Karwatowska‐Prokopczuk, E., Tardif, J., Gaudet, D., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Amour, E. S., Alexander, V. J., Xia, S., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.005 · Cited by 51
Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence
Bhat, S. Z., Sarkar, S., Zaffar, D., Dandona, P., & Kalyani, R. R. (2023) · Current Cardiology Reports · doi:10.1007/s11886-022-01831-0 · Cited by 51
Lee, S. J., Kim, S.-E., Go, T., Kang, D. R., Jeon, H.-S., Kim, Y., Cho, D., Park, Y. J., Lee, J., Lee, J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad036 · Cited by 51
Sniderman, A. D., Langlois, M., & Cobbaert, C. M. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000754 · Cited by 49
Bell, J. A., Richardson, T. G., Wang, Q., Sanderson, E. C. M., Palmer, T., Walker, V. M., O’Keeffe, L. M., Timpson, N. J., Cichońska, A., Julkunen, H., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100457 · Cited by 47
Elliott, P. S., Kharaty, S. S., & Phillips, C. M. (2022) · Nutrients · doi:10.3390/nu14245371 · Cited by 53
Chen, J., Fang, Z., Luo, Q., Wang, X., Warda, M., Das, A., Oldoni, F., & Luo, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01993-y · Cited by 47
Johansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315639 · Cited by 43
Self-citationPropolis in Metabolic Syndrome and Its Associated Chronic Diseases: A Narrative Review
Zulhendri, F., Ravalia, M., Kripal, K., Chandrasekaran, K., Fearnley, J., & Perera, C. O. (2021) · Antioxidants · doi:10.3390/antiox10030348 · Cited by 52
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease
Ganda, O. P. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000875 · Cited by 45
Biosynthesis and Metabolism of ApoB-Containing Lipoproteins
Borén, J., Taskinen, M., & Packard, C. J. (2024) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062222-020716 · Cited by 46
Long-term fasting improves lipoprotein-associated atherogenic risk in humans
Grundler, F., Plonné, D., Mesnage, R., Müller, D., Sirtori, C. R., Ruscica, M., & de Toledo, F. W. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02578-0 · Cited by 40
Lorenzatti, A. J., Monsalvo, M. L., López, J. A. G., Wang, H., & Rosenson, R. S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01287-6 · Cited by 34
Li, L., Liu, Z., Quan, J., Sun, J., Lu, J., & Zhao, G. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113736 · Cited by 32
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320175 · Cited by 33
Self-citationLi, K., Fan, F., Zheng, B., Jia, J., Liu, B., Liu, J., Chen, C., Zhou, J., Zhang, Y., & Huo, Y. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01490-0 · Cited by 31
Xiao, Z., Lin, Z., Xu, L., Xu, W., Huang, H., Wang, Y., Cao, S., Xie, Z., Liao, W., Liao, Y., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad297 · Cited by 30
Aaseth, E., Halvorsen, S., Helseth, R., & Gravning, J. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf104 · Cited by 30
Pan, X., & Hussain, M. M. (2021) · Hepatology · doi:10.1002/hep.32196 · Cited by 28
Remnant cholesterol in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
Delialis, D., Georgiopoulos, G. A., Aivalioti, E., Konstantaki, C., Oikonomou, E., Bampatsias, D., Mavraganis, G., Vardavas, C. I., Liberopoulos, E. N., Stellos, K., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.04.007 · Cited by 31
Zimerman, A., Wiviott, S. D., Park, J., Murphy, S. A., Ran, X., Bramson, C., Curto, M., Ramos, V., Jevne, A., Kuder, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae090 · Cited by 28
Skudder‐Hill, L., Sequeira, I. R., Ko, J., Cho, J., Poppitt, S. D., & Petrov, M. S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15233 · Cited by 26
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25
Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review
Zubirán, R., Neufeld, E. B., Dasseux, A., Remaley, A. T., & Sorokin, A. V. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00376-3 · Cited by 30
He, X., Zou, R., Du, X., Li, K.-T., & Sha, D.-J. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01995-w · Cited by 20
Residual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 29
Self-citationMasuda, R., Wist, J., Lodge, S., Kimhofer, T., Hunter, M. L., Hui, J., Beilby, J. P., Burnett, J. R., Dwivedi, G., Schlaich, M. P., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.06.004 · Cited by 22
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 22
Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 24
Wang, S., Zhang, Q., & Qin, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-55282-4 · Cited by 24
Krauss, R. M., Remaley, A. T., & Chapman, M. J. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.02.007 · Cited by 22
Zafrir, B., Khoury, R., & Saliba, W. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.03.009 · Cited by 20
Bruemmer, D., & Cho, L. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.012615 · Cited by 18
Lipidomics of triglyceride‐rich lipoproteins derived from hyperlipidemic patients on inflammation
Moreno‐Vedia, J., Llop, D., Rodríguez‐Calvo, R., Plana, N., Amigó, N., Rosales, R., Esteban, Y., Masana, L., Ibarretxe, D., & Girona, J. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14132 · Cited by 19
Cui, C., Li, P., Qi, Y., Song, J., Han, T., Shang, X., Balmer, L. A., Sheng, C., Zha, Y., Xu, Z., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035764 · Cited by 17
Social Bonds Retain Oxytocin-Mediated Brain-Liver Axis to Retard Atherosclerosis
Ko, S., Anzai, A., Liu, X., Kinouchi, K., Yamanoi, K., Torimitsu, T., Ichihara, G., Kitakata, H., Shirakawa, K., Katsumata, Y., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.324638 · Cited by 19
Kumarapperuma, H., Chia, Z.-J., Malapitan, S. M., Wight, T. N., Little, P. J., & Kamato, D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118552 · Cited by 19
Hvid, K., Balling, M., Afzal, S., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf203 · Cited by 15
Self-citationLiu, D., Zhang, Y. P., Wang, C., & Zuo, H. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.033 · Cited by 14
Xu, S., Liu, Y., Wang, Q., Liu, F., Xian, Y., Xu, F., & Liu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1308002 · Cited by 13
Ma, S., Xia, M., & Gao, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.681444 · Cited by 14
Yoshida, H., Ito, K., Manita, D., Sato, R., Hiraishi, C., Matsui, S., & Hirowatari, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.756057 · Cited by 14
Girona, J., Guardiola, M., Barroso, E., García‐Altares, M., Ibarretxe, D., Plana, N., Ribalta, J., Amigó, N., Correig, X., Vázquez‐Carrera, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052039 · Cited by 13
Effects of physical activity on the levels of remnant cholesterol: A population‐based study
Chen, J., Luo, Q., Su, Y., Wang, J., Fang, Z., & Luo, F. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18062 · Cited by 14
Toth, P. P., & Banach, M. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae057 · Cited by 13
Martini, T., Gobet, C., Salati, A., Blanc, J., Mookhoek, A., Reinehr, M. D., Knott, G. W., Sordet‐Dessimoz, J., & Naef, F. (2024) · Nature Communications · doi:10.1038/s41467-024-52751-2 · Cited by 14
Kapoor, K., Alfaddagh, A., Stone, N. J., & Blumenthal, R. S. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.06.004 · Cited by 14
Rehues, P., Girona, J., Guardiola, M., Plana, N., Scicali, R., Piro, S., Muñiz-Grijalvo, O., Díaz-Díaz, J. L., Recasens, L., Pinyol, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032319 · Cited by 12
Wen, P., Shi, L., Huang, Q., Li, T., Jian, W., Zhao, L., Xu, R., Liu, T., Zhang, B., Wang, H., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.174754 · Cited by 12
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae222 · Cited by 12
Self-citationCastelblanco, E., Hernández, M., Ortega, E., Amigó, N., Real, J., Granado-Casas, M., Miñambres, I., López‐Cano, C., Lecube, A., Bermúdez-López, M., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109145 · Cited by 12
Yang, Z., Yang, K., Shi, J., Yang, Q., Zhang, Y., Gao, J., Shi, D., & Qu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.913977 · Cited by 12
Razavi, A. C., Bazzano, L., He, J., Krousel-Wood, M. A., DORANS, K. S., Razavi, M. A., Fernandez, C., Whelton, S. P., & Kelly, T. N. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100190 · Cited by 11
Liu, T., Zhao, D., Wang, M., Sun, J., Liu, J., Li, J., Duan, Y., Hu, P., Sun, Z., Liu, J., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63937 · Cited by 11
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 12
Self-citationBorén, J., Packard, C. J., Nordestgaard, B. G., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf214 · Cited by 12
Self-citationYu, D., Shen, S., Zhang, J., & Wang, Q. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.008 · Cited by 11
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Nielsen, S. F. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120551 · Cited by 13
Self-citationDietary management of dyslipidemia
Chopra, A. K. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.005 · Cited by 13
Li, T., Zhu, P., Song, Y., Tang, X., Gao, Z., Run-Lin, G. A. O., & Yuan, J. (2023) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2023.12.001 · Cited by 12
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Mortensen, M. B., Langsted, A., Nordestgaard, B. G., & Afzal, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120471 · Cited by 13
Self-citationRehues, P., Rodríguez, M. M., Alvarez-Borillo, J., Jiménez, M. P. C., Melià, A., Sempere, M., Balsells, C., Castillejo, G., Guardiola, M., Castro, A., et al. (2021) · Biomolecules · doi:10.3390/biom12010047 · Cited by 10
Guo, M., Li, M., Chen, L., Wang, H., Wang, J., Niu, P., & Ma, J. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.114763 · Cited by 10
Zubirán, R., Vargas‐Vázquez, A., Razo-Olvera, F. M. D., Cruz‐Bautista, I., Martagón, A. J., Sampson, M. L., Remaley, A. T., & Aguilar-Salinas, C. A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117364 · Cited by 10
VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., Smith, G. D., & Nielsen, S. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119094 · Cited by 9
Self-citationAmigó, N., Torné, P., Nordestgaard, L. T., Barbagallo, F. D. G., Merino, C., Magni, P., González-Lleó, A. M., Andreychuk, N., Catapano, A. L., Masana, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178284 · Cited by 10
Johansen, M. Ø., Moreno‐Vedia, J., Balling, M., Smith, G. D., & Nordestgaard, B. G. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117316 · Cited by 10
Self-citationDeng, K., Pan, X., Voehler, M., Cai, Q., Cai, H., Shu, X., Gupta, D. K., Lipworth, L. P., Zheng, W., & Yu, D. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034364 · Cited by 8
Yang, R., Wu, S., Zhao, Z., Deng, X., Deng, Q.-Y., Wang, D., & Liu, Q. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02420-7 · Cited by 8
Kunkel, K. J., Lemor, A., Mahmood, S., Villablanca, P., & Ramakrishna, H. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.07.032 · Cited by 8
Association of lipid profile with obesity among breast cancer survivors: a cross-sectional study
Okekunle, A. P., Yie, G.-E., Song, S., Kim, Z., Youn, H. J., Cho, J., Min, J. W., Kim, Y. S., & Lee, J. E. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01674-2 · Cited by 8
Predictive value of ApoB/ApoA-I for recurrence within 1 year after first incident stroke
Lin, J., Si, Z., & Wang, A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2023.1308442 · Cited by 7
Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
Guardiola, M., Rehues, P., Amigó, N., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Girona, J., Martínez‐Montoro, J. I., Ortega, E., Pérez, A., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14214 · Cited by 7
Chao, T.-H., Lin, T., Cheng, C., Wu, Y., Ueng, K., Wu, Y., Lin, W.-W., Leu, H.-B., Cheng, H., Huang, C., et al. (2024) · PubMed Central · doi:10.6515/acs.202409_40(5).20240724a · Cited by 7
Balling, M., Afzal, S., Varbo, A., Nordestgaard, B. G., & Langsted, A. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae217 · Cited by 10
Self-citationAnorexia Nervosa Is Associated with a Shift to Pro-Atherogenic Low-Density Lipoprotein Subclasses
Stadler, J. T., Lackner, S., Mörkl, S., Meier‐Allard, N., Scharnagl, H., Rani, A., Mangge, H., Zelzer, S., Holasek, S. J., & Marsche, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040895 · Cited by 7
Liu, X., Li, Y., Wan, X., Zhuang, P., Wu, Y., Zhang, L., Yang, A., Yao, J., Zhang, Y., & Jiao, J. (2023) · Nutrients · doi:10.3390/nu15143176 · Cited by 7
Metadata
- Authors
- Balling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Nordestgaard, Børge G.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 76
- Issue
- 23
- Pages
- 2725-2735
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3107369671
- Cited by
- 175
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 39 · 2023: 35 · 2022: 24 · 2021: 39 · 2020: 1
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- University of Bristol (MC_UU_00011/1)
- Novo Nordisk Fonden (NNF18OC0052893)
- Hjerteforeningen (18-R124-A8511-22089)
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein B, apoB-containing lipoproteins, VLDL cholesterol, VLDL triglycerides, intermediate-density lipoprotein cholesterol, LDL cholesterol, myocardial infarction risk, atherosclerotic cardiovascular disease, lipoprotein fractions, Copenhagen General Population Study, smoking, systolic blood pressure
- MeSH terms
- Aged, Apolipoproteins B, Denmark, Female, Humans, Lipoproteins, VLDL, Male, Middle Aged, Myocardial Infarction, Risk, Triglycerides, Cholesterol, VLDL, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
